ZIP CODE FOR DELIVERES: 19801

WERITAS LAW FIRMS WORLDWIDE

www bayardfirm com

302-655-5000 (Fax) 302-658-6395

WRITER'S PARISTA 208 ESS rkirk@bayardfirm.com

FILED ELECTRONICALLY

Case 1:06-cv-00113-JJF

July 23, 2007

The Honorable Mary Pat Thynge United States District Court for the District of Delaware 844 North King Street, Lock Box 8 Wilmington, DE 19801

> Sepracor Inc. v. Dey, L.P. and Dey, Inc., RE: C.A. Nos. 06-113-*** & 06-604-*** (Consolidated Cases)

Dear Magistrate Judge Thynge:

Plaintiff Sepracor Inc. ("Sepracor") moves pursuant to paragraph 11(a) of the Amended Stipulated Protective Order (D.I. 165)¹ for an order directing that defendants Dey, L.P. and Dey, Inc. ("Dey") not disclose Sepracor's Confidential Information² to Dev's independent expert, Martin J. Adelman ("Adelman").

On June 25, 2007, Dev's counsel wrote to Sepracor's counsel identifying Adelman as an independent expert to whom Dey wished to disclose Sepracor's Confidential Information. Pursuant to the Protective Order, Dey's counsel enclosed Adelman's curriculum vitae, declaration and a listing of prior testimony. See Exhibit A.

Sepracor's review of Adelman's resume and listed testimony showed that Adelman's area of expertise is patent law and procedure, not chemistry or pharmacology. On July 2, 2007, and pursuant to the Protective Order, Sepracor's counsel wrote to Dey's counsel objecting to Dey's proposed disclosure of Confidential Information to Adelman. See Exhibit B. Sepracor's objection to disclosure is that, since the Court does not normally permit testimony by expert witnesses in patent law and procedure, Adelman would not be a testifying expert and, therefore, disclosure to him of Sepracor's Confidential Information was unnecessary.

In a response on July 5, 2007 (Exhibit C), Dey's counsel did not argue that Adelman was an expert in anything other than patent law and procedure. Instead, counsel

¹ Some of the acts referred to herein took place under the original Stipulated Protective Order entered in this case (D.I. 42). By agreement, the original Stipulated Protective Order has been amended (D.I. 165). The amendments did not affect any of the matters presented herein. Accordingly, this letter will refer simply to the "Protective Order" for convenience.

² In this letter, "Confidential Information" is used as defined in the Protective Order.

The Honorable Mary Pat Thynge Monday, July 23, 2007

Page 2 of 4

asserted the belief that the Court would permit expert testimony on those subjects. Counsel also argued that Dey should be allowed to disclose Sepracor's Confidential Information to Adelman even if he were not a testifying expert.

Here, Sepracor maintains its position that Dey should be prohibited from disclosing Sepracor's Confidential Information to Adelman.

The Court Should Not Permit Expert Legal Testimony on Patent Law and Procedure

The judges of this Court have long prohibited expert legal testimony on patent law and procedure. Specific examples of guidelines stating this principle have been published by Judge Robinson (Exhibit D) and Judge Jordan (Exhibit E). In fact, until his elevation to the Third Circuit, Judge Jordan was assigned to these consolidated cases, and so all parties had advance warning that, under Judge Jordan, "(e)xpert' legal testimony (as opposed to technical testimony) on such substantive issues as invalidity (by anticipation, obviousness, on-sale bar, prior conception, etc.) and claim construction and infringement will also not be permitted." See also Cryovac Inc. v. Pechiney Plastic Packaging, Inc., 430 F. Supp. 2d 346, 364 (D. Del. 2006) (Jordan, J.) (citing Revlon Consumer Prods. Corp. v. L'Oreal S.A., C.A. No. 96-192-MMS, 1997 WL 158281, at *3 (D. Del. Mar. 26, 1997)(Schwartz, J.)(excluding testimony on substantive issues of patent law, including inequitable conduct)); Syngenta Seeds, Inc. v. Monsanto Co., C.A. No. 02-1331-SLR, 2004 WL 2106583, at *2 (D. Del Sept. 8, 2004) (Robinson, J.) (excluding Adelman's proffered testimony). Dey is misguided to think that Adelman will be allowed to present expert legal testimony on patent law and procedure in these consolidated cases, any more than he was permitted to do so in Syngenta Seeds.

Sepracor does not anticipate either party being allowed to present expert legal testimony on patent law and procedure. Because of this Court's guidelines and legal precedent, Sepracor has not retained, and does not at this time wish to retain, an expert witness to counter any expert legal testimony on patent law and procedure proffered by Dey. Accordingly, to save unnecessary expense at the threshold, Sepracor requests a ruling that Adelman's expert legal testimony on patent law and procedure will not be permitted. Then, the question may be narrowed to whether Dey may disclose Sepracor's Confidential Information to Adelman as its consulting expert.

Dev Should Not Disclose Sepracor's Confidential Information to Adelman

The Protective Order allows the party's to disclose Confidential Information to their independent experts or consultants, subject to the specific provisions of the Protective Order, but most importantly that disclosure may only be made "solely for the purpose of assisting in this action." Protective Order ¶2(e) (emphasis added).

While Sepracor does not take issue generally with the notion that a party may retain an expert or consultant who will not testify, Sepracor is legitimately concerned about disclosure to Adelman, for at least two reasons, one general and one specific.

THE BAYARD FIRM

The Honorable Mary Pat Thynge Monday, July 23, 2007

First, Sepracor respectfully reminds the Court that Dey proposes to disclose to Adelman Sepracor's Confidential Information. That would not cover patent prosecution histories or other public documents, which Dey may share with Adelman at will. Rather, Sepracor's Confidential Information is highly sensitive technical information related to product development and product success. Adelman does not have narrow technical expertise; rather he is a patent law generalist. The extensive list of matters Adelman submitted with his resume shows involvement in a tremendous number of lawsuits involving pharmaceutical companies, a great many of them Sepracor's competitors. Sepracor is concerned about the disclosure of its sensitive and confidential technical information to someone who holds himself out so regularly as an expert on the most general of topics. Balanced against that concern is Dey's asserted need for Adelman to supplement the admitted expertise of Dey's outside counsel in patent law and procedure. Sepracor respectfully asks the Court to strike that balance on the side of confidentiality and forbid disclosure of Sepracor's Confidential Information to Adelman.

Second, in the initial letter proposing disclosure to Adelman (Exhibit A), Dey's counsel admits that Dey has contacted Adelman "concerning participation in the *Dey v. Sepracor* case, Civ. Action No. 1:07-cv-2353." For the Court's edification, that case is a case brought this year by Dey against Sepracor in the Southern District of New York alleging Sepracor's infringement of Dey's patents which, *inter alia*, are directed to a composition comprising the compound formoterol, a different product from those at issue in the present cases, but a product in the same general category of products (respiratory inhalation solutions). Dey's outside counsel in New York is the same outside counsel as their outside counsel here. Sepracor is most concerned about the disclosure of its Confidential Information from these consolidated cases to Adelman, who will likely be a witness or consultant against Sepracor in New York, where, as discussed above, Dey's asserted need to disclose technical information to Adelman in Delaware is not supported.

For the foregoing reasons, Sepracor respectfully moves pursuant to paragraph 11(a) of the Amended Stipulated Protective Order (D.I. 165) for an order directing that Dey not disclose Sepracor's Confidential Information to Adelman.

Respectfully submitted,

Muhand Keel Richard D. Kirk (rk0922)

Exhibits

Unreported cases

cc: Original to Court, by hand

All counsel of record as shown on attached service list

CERTIFICATE OF SERVICE

The undersigned counsel certifies that, on July 23, 2007, he electronically filed the foregoing document with the Clerk of the Court using CM/ECF, which will send automatic notification of the filing to the following:

Steven J. Balick, Esquire John G. Day, Esquire Tiffany Geyer Lydon, Esquire Ashby & Geddes 500 Delaware Avenue, 8th Floor PO Box 1150 Wilmington, Delaware 19899

The undersigned counsel further certifies that, on July 23, 2007, copies of the foregoing document were sent by email and hand to the above local counsel and by email and first class mail to the following non-registered participant:

Edgar H. Haug, Esquire Kimberly J. McGraw, Esquire Frommer, Lawrence & Haug L.L.P. 745 Fifth Avenue New York, NY 10151

Elizabeth A. Leff, Esquire Frommer, Lawrence & Haug L.L.P. 1667 K. Street, N.W. Washington, D.C. 20006

/s/ Richard D. Kirk (rk0922)
Richard D. Kirk

EXHIBIT A

FLH FROMMER LAWRENCE & HAUG LLP

New York

www.flhlaw.com

Tokyo

745 Fifth Avenue

New York, NY 10151

Washington, DC

Telephone: (212) 588-0800 Fax: (212) 588-0500

June 25, 2007

John Josef Molenda, Ph.D. JMolenda@fihlaw.com

VIA E-MAIL

Re:

Sepracor Inc. v. Dey, L.P., Inc.,

Civil Action Nos. 06-113-*** and 06-604*** (consolidated)

Dear Ms. Dadio:

Pursuant to paragraph 11 of the Protective Order, Dey identifies Professor Martin Adelman as an independent expert in this case. As such, I attach the following: (1) Professor Adelman's curriculum vitae, (2) his declaration (from Exhibit A of the Protective Order), (3) a list of all cases in which Professor Adelman has been deposed as a patent expert, and (4) a list of all cases in which he has appeared in court as a patent expert.

To his knowledge, Professor Adelman has had no relationship or connection with Sepracor, Inc. Dey has contacted Professor Adelman concerning participation in the *Dey v. Sepracor* case, Civ. Action No. 1:07-cv-2353.

Yours sincerely,

John Josef Molenda

JJM/jjm

Attachments

GEORGE WASHINGTON UNIVERSITY

Professional Record

Name: Martin J. Adelman

Office Address:

George Washington University Law School

700 20th St. N.W.

Washington, D.C. 20052 Phone: (202) 994-7703

madelman@law.gwu.edu

Date Prepared: September, 2005

Home Address:

29820 Woodland Drive Southfield, MI 48034

Phone: (248)356-7553

Fax: (248)356-7554

Present Position:

Theodore and James Pedas Family Professor of Intellectual Property and Technology Law, Co-Director of the Intellectual Property Program and Co-Director of the Dean Dinwoodey Center for Intellectual Property Studies, George Washington University Law School.

Date and Place of Birth:

February 22, 1937, Detroit, Michigan.

Citizen of: U.S.A.

Education

High School: Central High School, Detroit, Michigan, June 1954.

Baccalaureate: A.B., University of Michigan, Ann Arbor, Michigan, June, 1958.

Graduate: M.S. (Physics), University of Michigan, Ann Arbor, Michigan, August, 1959.

Law Degree: University of Michigan, Ann Arbor, Michigan, June, 1962.

Other Faculty Appointments

Professor of Law, Wayne State University Law School, Detroit MI, 1973-1999, Professor Emeritus 1999--.

Visiting Professor of Law, University of Michigan Law School, Ann Arbor, Michigan, Winter 1982.

Visiting Professor of Law and Acting Director of the Intellectual Property program, George Washington University Law School, 1998-99.

Professional Experience

Résumé of Martin J. Adelman

page 2

Assistant Editor Michigan Law Review (1960-1962).

Research Assistant to Professor Samuel D. Estep (1960-1962).

Law Clerk, Chief Judge Theodore Levin, Federal District Court, Detroit, Michigan (1962-1963)

Associate, Honigman, Miller, Schwartz & Cohn, Detroit, Michigan (1963-64).

Patent Attorney, Burroughs Corp., Washington, D.C. (1964-1965).

Associate, Barnard, McGlynn & Reising, Birmingham, Michigan (1965-1968), Partner (1968-1973) in charge of patent, patent-antitrust, and related litigation.

Professional Society Memberships:

American Bar Association,
American Intellectual Property Law Association,
Michigan Bar Association,
International Association for the Advancement of Teaching and Research in Intellectual
Property.

Service at Wayne State University

Acting Dean, Law School (1974-75). President, Faculty Senate (1976-1979). Chair, Personnel Committee, Law School (1987-88).

Professional Consultation

Testified as an expert on patent law and practice either at trial or by way of deposition in more than 180 patent infringement cases.

Journal/Editorial Activity

Book Review Editor, The Antitrust Bulletin, 1980-1986.

Publications

Scholarly Books

Patent Law Perspectives, 2d Ed., Matthew Bender (eight volumes)(continuously

Page 5 of 22

updated)(available through LEXIS).

Cases and Materials on Patent Law, 2nd edition (with Randall R. Rader, John R. Thomas and Harold C. Wegner), West Group 2003.

Chapter 63, *Patents*, in *Business and Commercial Litigation in Federal Courts* (six volumes)(continuously updated)(with Randall R. Rader and Harold C. Wegner) West Group 1998 (available through WESTLAW).

Journal Articles

Refereed Papers:

An Antitrust Decision: Lear v. Adkins, 58 A.B.A.J. 45 (1972).

Territorial Restraints in International Technology Agreements after *Topco*, 17 Antitrust Bull. 763 (1972) (with Brooks), reprinted at 5 Pat. L. Rev. 457 (1973).

The Supreme Court, Market Structure, and Innovation: Chakrabarty, Rohm and Haas, 27 Antitrust Bull. 457 (1982).

Invited Articles:

Secrecy and Patenting: Some Proposals for Resolving the Conflict, 1 A.P.L.A. Quarterly J. 296 (1973), reprinted at 5 Pat. L. Rev. 57 (1973).

Relevant Market Paradox - Attempted and Completed Patent Fraud Monopolization, 28 Ohio State L.J. 289 (1977), reprinted at 10 Intellectual Property L. Rev. 115 and 8 J. of Reprints for Antitrust L. and Econ. 709.

Use of Industrial Property as a Clandestine Cartel, 30 (Supplement) Am. J. Comp. L. 1701 (1982).

Forward, Symposium: Perspectives on the General Motors-Toyota Joint Venture, 31 Wayne L. Rev. 1163 (1985).

The New World of Patents Created by the Court of Appeals for the Federal Circuit, 20 U. of Mich. J. L. Ref. 979 (1988).

Patents and the Seventh Amendment, Molengrafica, Eenvormig en vergelijkend privaatrecht 357 (1993).

Damages and other financial remedies for Patent Infringement, AIPPI Annuaire 1995/IX, 274 (1995).

Prospects and Limits of the Patent Provision in the TRIPS Agreement: The Case of India, 29 Vand. J. Tranat'l L. 507 (1996)(with Baldia).

The Effect of the Seventh Amendment on Substantive American Patent Law, Molengrafica, Europees Privaatrecht 173 (1996).

The Exhaustion Doctrine in American Patent Law, Molengrafica, Europees Privaatrecht 247 (1997).

NonRefereed Papers:

State Control of Radiation Hazards: An Intergovernmental Relations Problem, 60 Mich. L. Rev. 41 (1961) (with Estep).

Trade Secrets and Federal Pre-exemption - The Aftermath of Sears and Compco, 49 J. Pat. Off. Soc'y 713 (1967).

Inventions and the Law of Trade Secrets after *Lear v. Adkins*, 16 Wayne L. Rev. 77 (1969) (with Jaress), reprinted at 3 Pat. L. Rev. 231 (1971).

Patent-Antitrust Law: A New Theory, 17 Wayne L. Rev. 1 (1971) (with Jaress), reprinted at 3 Pat. L. Rev. 231 (1971).

The Integrity of the Administrative Process, Sherman Section 2 and the Per Se Rules - Lessons of Fraud on the Patent Office, 19 Wayne L. Rev. 1 (1972) (with Brooks), reprinted at 55 J. Pat. Off. Soc'y 255 (1973) and 5 Pat. L. Rev. 413 (1973).

Patent-Antitrust: Patent Dynamics and Field of Use Licensing, 50 N.Y.U. L. Rev. 273 (1975) (with Juenger), reprinted at 7 Pat. L. Rev. 495, and 8 J.of Reprints for Antitrust L. and Econ. 429.

Property Rights Theory and Patent-Antitrust: The Role of Compulsory Licensing, 52 N.Y.U. L. Rev. 77 (1977), reprinted at 10 Intellectual Property L. Rev. 77 and 8 J. of Reprints for Antitrust L. and Econ. 287.

The Doctrine of Equivalents in Patent Law: Questions Pennwalt did not Answer, 137 U. of Penn. L. Rev. 673 (1989) (with Francione).

Is the Use of the Doctrine of Equivalents to Fix Mistakes a Mistake?, 27 N. Ky. L. Rev. 1021 (2000).

Book Reviews

Résumé of Martin J. Adelman

page 5

Academic Journals

Book Review, 25 Antitrust Bull. 891 (1980).

Book Review, 26 Antitrust Bull. 447 (1981).

Book Review, 27 Antitrust Bull. 275 (1982).

Book Review, 28 Antitrust Bull. 491 (1983).

EXHIBIT A

IN THE UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

SEPRACOR INC.,	; ;	
Plaintiff,	; ;	•
ν.	: Civil Action No. 06-113-KAJ	:
DEY, L.P., and DEY, INC.,		
Defendant.		,
	production (
1. My home address is 298 2. My present employer is 200	DECLARATION Verification South fee AMT 192 West. University School present 48034	
employer is 200	H. St. NW, Washing Loute Th	0/257
3. My present occupation or job d	description is Infessor of Law	
4. I have carefully read and understand the provisions of the Stipulated Protective Order in		
this case approved by the U. S. District Court Judge Kent A. Jordan on		

provisions of the Stipulated Protective Order.

5. I will hold in confidence and not disclose to anyone any Confidential Information or any words, summaries, abstracts or indices of Confidential Information disclosed to me, except in accordance with the Stipulated Protective Order.

- 6. I shall not use or refer to any of the documents, things, and/or any information designated under the Stipulated Protective Order other than in connection with this litigation and as prescribed in the Stipulated Protective Order.
- 7. Upon notification that this litigation has terminated, or at such earlier time as requested by the counsel or party by whom I am employed or retained, I will return all documents and things designated as containing Confidential Information, and all summaries, abstracts and indices thereof, which come into my possession, and documents or things which have been prepared relating thereto, to counsel for the party by whom I am employed or retained.
- 8. I do and shall subject myself to the continuing jurisdiction of the above-entitled Court over my person, wherever I shall be found, for purposes of enforcement of the Stipulated Protective Order.

9. I declare under penalty of perjury that the foregoing is true and correct.

By: Martin	Malwar
	7

Subscribed and sworn to before me

day of ,2006.

Notary Public

My Commission Expires:

- 1. Sandvik v. Waukesha,* 640 F. Supp. 1139 (E.D. Wisc. 1986).
- 2. Coleco* v. Mattel, 79 Civ 4909 (S.D.N.Y.). (Davis Hoxie, New York, N.Y.)
- 3. Hemstreet v. Burroughs,* 1988 WL 93121 (Fed. Cir. 1988).
- 4. Ransburg v. Behr,* No. 80 74003 (E.D. Mich.).
- 5. Anthes v. Aluma,* No. 81-1877 (E.D. Pa.).
- 6. Horiba v. Beckman,* (E.D. Mich.).
- 7. Norfin* v. A.M., Case No. 82-B-4922 (N.D. Ill.).
- 8. Johns-Manville* v. Guardian, 13 U.S.P.Q.2d 1684 (E.D. Mich. 1989).
- 9. Multi-Arc* v. Vac-Tec Systems, Inc., Civil No. H-85-6893 (D. Minn.). (Arnold White, Houston, Texas)
- Afros, S.p.A.* v. Krauss-Maffei, 671 F. Supp. 1402
 Del. 1987).
- 11. Truswal v. Gang-Nail,* discussed at 2 U.S.P.Q.2d 1034 (Fed. Cir. 1987).
- 12. Qume v. Toma* (ITC). (Baker & McKenzie, Washington, D.C.)
- 13. Abbott Laboratories v. Brennan,* 21 U.S.P.Q.2d 1192 (Fed. Cir. 1991).
- 14. Hughes Aircraft v. Ford Aerospace,* discussed in 8 U.S.P.Q.2d 1989 (Cl. Ct. 1989).
- 15. Lubrizol* v. Ethel (D. Del). (Jones Day, Cleveland, Ohio)
- 16. Bilgutay v. NCR*
 (Davis Hoxie, New York, N.Y.)
- 17. Deuer* v. Kent, 1990 WL 78997 (Fed. Cir. 1990).
- 18. Lever Bros.* v. Proctor & Gamble, 5 U.S.P.Q.2d 1239 (D.N.J. 1987).
- 19. Paramount v. Weyerhauser*

- 20. Pall* v. Cuno, 14 U.S.P.Q.2d 1815 (E.D.N.Y. 1989).
- 21. DuPont v. Polaroid Graphics,* 10 U.S.P.Q.2d 1579 (D.Del 1989).
- 22. ICI* v. Barr, 22 U.S.P.Q.2d 1906 (S.D.N.Y. 1992).
- 23. Rohm & Haas v. NL* (Burns Doane, Washington D.C.)
- 24. Weldotron* v. Hobart (Davis Hoxie, New York, N.Y.)
- 25. Information Resources* v. Test Marketing, 19 U.S.P.Q.2d 1743 (S.D. Ohio 1991).
- 26. Leonard Studio* v. Desmar Corp., discussed at 18 U.S.P.Q.2d 1565 (Fed. Cir. 1991).
- 27. Advanced Cardiovascular Systems v. Scimed Life Systems,* 12 U.S.P.Q.2d 1539 (Fed. Cir. 1989).
- 28. Baxter v. Abbott*
 (Jones Day, Chicago, Illinois)
- 29. Smith v. Amerson* (Christie Parker, Pasadena, California)
- 30. Hercules v. B.F. Goodrich* (Jones Day, Cleveland, Ohio)
- 31. Cadtrak v. Commodore*
 (Fish & Neave, New York, N.Y.)
- 32. Mabuchi* v. Johnson Controls, 1992 WL 276680 (Fed. Cir. 1992).
- 33. Burroughs-Wellcome v. Novopharm,* 29 U.S.P.Q.2d 1721 (E.D.N.C. 1993).
- 34. Gambro v. Baxter* (McAndrews, Held & Malloy, Chicago, Illinois)
- 35. Cyrix* v. Intel, 846 F. Supp. 522 (E.D. Tex. 1994).

- 36. Merck v. Alcon*
 (Fish & Neave, New York, N.Y.)
- 37. Nellcor* v. BOC Health Care (Fish & Neave, New York, N.Y.)
- 38. General Electric* v. Emerson (Welsh & Katz, Chicago, Illinois)
- 39. Lemelson v. Ford*
 (Fish & Neave, New York)
- 40. Lockwood* v. American Airlines (Lyon & Lyon, Costa Mesa, California)
- 41. Medical Graphics v. SensorMedics* (Lyon & Lyon, Los Angeles, California)
- 42. Stark* v. Advanced Magnetics (Goodwin, Procter, Boston, Mass.)
- 43. Abbott* v. Alra (Jones Day, Chicago)
- 44. Cury* v. Philip Morris (Pennie & Edmonds, New York, N.Y.)
- 45. Cochlear v. Advanced Bionics* (Fish & Neave, New York, N.Y.)
- 46. Lyndex v. Richmill*
 (Loeb & Loeb, Los Angeles, California)
- 47. Pitney Bowes, Inc. v. Sudbury Systems*
 (Nutter, McClennen & Fish, LLP, Boston, Mass.)
- 48. C.S. Telecom v. Hewlett-Packard* (Pennie & Edmonds, New York, N.Y.)
- 49. Nagel v. Ford Motor*
 (Rader, Fishman & Grauer, Bloomfield Hills, MI)

- 50. Motorola* v. Rockwell (Fish & Neave, New York, N.Y.)
- 51. Ampex* v. Mitsubishi (Fish & Neave, New York, N.Y.)
- 52. Altera* v. Xilinx (Sullivan & Cromwell, New York, N.Y.)
- 53. Abbott* v. Geneva and Novopharm (Jones, Day, Chicago, Illinois)
- 54. Pitney-Bowes v. Hewlett-Packard* (Pennie & Edmonds, New York, N.Y.)
- 55. Varian* v. Lamb (Fish & Neave, New York, N.Y.)
- 56. Lockheed* v. Silicon Graphics (Scully, Scott, Murphy & Presser, Garden City, N.Y.)
- 57. Upjohn v. Mova Pharmaceutical* (Burns, Doane, Swecker & Mathis, Alexandria, Virginia)
- 58. PLC v. Cardiogenesis* (Lyon & Lyon, Los Angeles, CA.)
- 59. Berlex v. Biogen*
 (Hale & Dore, Boston, Mass.)
- 60. Hitachi v. Samsung*
 (Foley & Lardner, Washington, D.C.)
- 61. Fischer v. Trex*
 (Fish & Richardson, Boston, Mass)
- 62. Shell Oil v. ICI*
 (Scully, Scott, Murphy & Presser, Garden City, New York)
- 63. Process Resources v. Delta*
 (Orrick, Herrington & Sutcliffe, New York, N.Y.)

- 64. Amazon.com v. Barnesandnoble.com* (Pennie & Edmonds, New York, N.Y.)
- 65. Kensey Nash v. Perclose*
 (Townsend and Townsend and Crew, San Francisco, CA)
- 66. Cordis* v. Boston Scientific (Patterson, Belknap et al. New York, N.Y.)
- 67. Advanced Energy Industries v. Astec America* (Fish & Neave, New York, N.Y.)
- 68. In the Matter of Hoechst Marion Roussel, Inc. (FTC, Washington DC)
- 69. Oxford Gene v. Affymetrix*
 (Orrick, Herrington & Sutcliffe, Palo Alto, CA)
- 70. U.S. Filter* v. Ionics (Hale and Dorr, Boston, MA)
- 71. Proctor & Gamble* v. Brita (Dorsey & Whitney LLP, Minneapolis, Minn.)
- 72. In the Matter of Certain Polyethylen Terephthalate Yarn (Pennie & Edmonds, Washington, D.C.)
- 73. Valitek v. Iomega* (Hale & Dorr, Boston, Mass.)
- 74. Dictaphone* v. Nice (Pennie & Edmonds, New York, N.Y.)
- 75. Mercexchange* v. Ebay (Hunton & Williams, Washington, D.C.)
- 76. Katz* v. Verizon (Fish & Neave, New York, N.Y.)
- 77. PharmaStem* v, Viacell (Perkins Coie LLP, Menlo Park, CA)

- 78. Glaxo Group* v. Ranbaxy (Morgan Lewis, New York, N.Y.)
- 79. Syngentia Seeds v. Dow Agrosciences* (Orrick, Herrington & Sutcliffe, New York, N.Y.)
- 80. Muniauction* v. Thomson Corp.* (Hale & Dorr LLP, Washington, DC)
- 81. In the Matter of Light-Emitting Diodes (Fish & Richardson, Washington D.C.)
- 82. In the Matter of Certain Personal Computers, Monitors and Components Thereof (DLA Piper Rudnick Gray Cary US LLP, San Diego, CA.)
- 83. SKB* v. Ranbaxy (Wilmer Cutler Pickering Hale & Dorr, Boston, Mass.)
- 84. Scimed* v. Medtronic (Jones Day, New York, NY)
- 85. Shire* v. Barr (Frommer Lawrence & Haug LLP, New York, NY)
- 86. Par* v. Roxane (Frommer Lawrence & Haug LLP, New York, NY)
- 87. Qualcomm v. Broadcom* (Wilmer Hale, Boston MA)
- 88. Qualcomm v. Broadcom* (McAndrews, Held & Malloy, Chicago, IL)
- 89. Semiconductor Energy Lab.* v. Chi Mei (Jenner & Block, Chicago, IL)
- 90. Amgen v. Roche (Kaye Scholer, New York, NY)

ARBITRATIONS

- 91. Acrison* v. Hyer Industries (Special Master James F. Davis) (Davis Hoxie, New York, N.Y.)
- 92. Kaiser* v. Government of Israel, (arbitration before Messrs Robert Rifkind, Evan Davis and Thomas Munno involving a comparison of Israeli and United States infringement law) (Collette & Erickson, San Francisco, California)
- 93. Varian Semiconductor v. Applied Materials (arbitration of patent dispute before Messrs John K. Uilkema, Harry F. Manbeck and Bryan Medlock) (Fish & Neave, Palo Alto, California)

- 1. Calderon v. G.M.,* 206 U.S.P.Q. 782 (E.D. Mich. 1980).
- 2. Oakwood Mfg., v. Novi American,* 212 U.S.P.Q. 261 (E.D. Mich.1981), 213 U.S.P.Q. 1014 (E.D. MI. 1982).
- 3. Mead Digital Systems* v. A.B. Dick, 213 U.S.P.Q. 328 (S.D. Ohio 1981).
- 4. General Battery v. Gould,* 215 U.S.P.Q. 1007 (D.Del. 1982).
- 5. RCA v. Applied Digital Data Systems,* 217 U.S.P.Q. 421 (D.Del. 1983), rev'd 221 U.S.P.Q. 385 (Fed. Cir. 1984).
- 6. Alco Standard v. Westinghouse,* 1 U.S.P.Q.2d 1337 (Fed. Cir. 1987).
- 7. Litton v. Whirlpool,* 221 U.S.P.Q. 97 (Fed. Cir. 1984).
- 8. Multifastener* v. MacLean-Fogg, 219 U.S.P.Q. 1074 (E.D. Mich. 1983).
- 9. Jackson-Jordan* v. Plasser American, 219 U.S.P.Q. 922 (E.D. Va. 1983).
- 10. Foseco International* v. Fireline, 226 U.S.P.Q. 33 (N.D. Ohio 1984).
- 11. Shatterproof* v. L.O.F., 225 U.S.P.Q. 634 (Fed. Cir. 1985).
- 12. Independent Die Association v. Ford Motor,* (E.D. Mich.). (Brooks & Kushman, Southfield, Michigan)
- 13. Stewart-Warner* v. City of Pontiac, 226 U.S.P.Q. 676 (Fed. Cir. 1985).
- 14. Witco Chemical v. Mobay,* 229 U.S.P.Q. 188 (Fed. Cir. 1986).
- 15. Tiegel Mfg v. Farmer Mold & Machine Works,* 225 U.S.P.Q. 1051(N.D. Fla. 1984).
- 16. Windsurfing* v. Bic Leisure, 227 U.S.P.Q. 927 (S.D.N.Y. 1985).
- 17. A.B.Dick v. Burroughs, * 230 U.S.P.Q. 849 (Fed. Cir. 1986).
- 18. Vieau v. Japax,* 230 U.S.P.Q. 500 (E.D. Mich. 1985).

- 19. Kaepa v. Payless Shoesource,* (W.D. Tex. 1985). (Cox & Smith, San Antonio, Texas)
- 20. Hybritech* v. Monoclonal Antibodies, 227 U.S.P.Q. 215 (N.D. Cal. 1985).
- 21. Key Tronic v. Burroughs,* 861 F.2d 729 (Fed. Cir. 1988).
- 22. Ricon* v. Adaptive Driving Systems, 229 U.S.P.Q. 731 C.D. Cal. 1986).
- 23. United States of America v. Telectronics,* 3 U.S.P.Q.2d 1571 (D.Col. 1987).
- 24. Andrew* v. Gabriel, 6 U.S.P.Q.2d 2011 (Fed. Cir. 1988).
- 25. ZMI v. Cardiac Resuscitator,* 2 U.S.P.Q.2d 1985 (D. Ore. 1987).
- 26. Napp* v. BASF, (S.D. Cal.). (Lyon & Lyon, Los Angeles, California)
- 27. Gabriel v. Andrew,* 2 U.S.P.Q.2d 1792 (D. Maine 1987).
- 28. Carl Cooper v. Harris,* 902 F.2d 43 (Fed. Cir. 1989).
- 29. Dana* v. IPC, 8 U.S.P.Q.2d 1692 (Fed. Cir. 1988).
- 30. Gemveto Jewelry* v. Cooper, 694 F. Supp. 1085 (S.D.N.Y. 1988).
- 31. Gould v. Control Laser,* 9 U.S.P.Q.2d 1718 (Fed. Cir. 1989).
- 32. Haworth* v. Steelcase, 8 U.S.P.Q. 2d 1001 (W.D. Mich 1988).
- 33. Dana* v. NOK, 11 U.S.P.Q.2d 1883 (Fed. Cir. 1989).
- 34. Freeman* v. Minnesota Mining & Manufacturing, 9 U.S.P.Q.2d 1111 (D.Del. 1988).
- 35. Laitram v. IBM,* (E.D. Va.). (Cravath, Swaine & Moore, New York, N.Y.)
- 36. Hughes v. United States,* 31 Fed. Cl. 481 (Cl. Ct. 1994).
- 37. Pioneer Research v. Wilson Laboratories,* 12 U.S.P.Q.2d 1432 (M.D. Cal.1989).

- 38. T.T.I.-Vend A. Video* v. Flixcorp of America, (S.D. Cal. 1989).
- 39. Standard Manufacturing v. United States,* 25 Cl. Ct. 1 (Cl. Ct. 1991).
- 40. National Semiconductor Corp. v. Linear Technology Corp.,* (N.D. Cal.). (Fish & Neave, New York, N.Y.)
- 41. Ralston Purina v. A. E. Staley,* 909 F.2d 1494 (Fed. Cir. 1990).
- 42. Polaroid* v. Kodak, 16 U.S.P.Q.2d 1481 (D. Mass. 1990).
- 43. Lemelson v. General Mills,* 968 F.2d 1202 (Fed. Cir. 1992).
- 44. Kearns v. Ford Motor,* 19 U.S.P.Q. 2d 1838 (E.D. Mich. 1990).
- 45. Envirotech* v. Amstar, (D. Utah). (Carl A. Rowold, Baker Hughes, Houston, Texas)
- 46. Corning Glass* v. Lightwave, 19 U.S.P.Q.2d 1838 (S.D.N.Y. 1991)
- 47. Arrow* & Howes v. Medcomp & AHS 16 U.S.P.Q.2d 1671 (E.D. Pa. 1990).
- 48. Ortho Pharmaceutical* v. American Home Products, 18 U.S.P.Q.2d. 1977 (E.D. Pa. 1990).
- 49. Solarex v. Arco Solar and Siemens Solar,* 805 F. Supp. 252 (D. Del. 1992).
- 50. Minnesota Mining & Manufacturing v. Johnson & Johnson,* 22 U.S.P.Q.2d 1401 (D. Minn. 1991).
- 51. Kingsdown v. Hollister,* 1992 U.S. Dist. LEXIS 11882 (N.D. Ill. 1992).
- 52. Molins PLC and Smith v. Textron,* 26 U.S.P.Q.2d 1889 (D. Del.1992).

- 53. Smith Carona v. Pelikan,* 784 F. Supp. 452 (M.D. Tenn. 1992). (Reed Smith, Pittsburg, Pennsylvania)
- 54. Stx, Inc.* v. Franklin Sports Indus., 1991 WL 114385 (Fed. Cir. 1991).
- 55. Chesebrough-Pond's USA* v. Benjamin Ansehl, 32 U.S.P.Q.2d 1225 (Fed. Cir. 1994).
- American Cyanamid* v. U.S. Surgical, 30 U.S.P.Q.2d 1561
 (D. Conn. 1992).
- 57. Kearns v. Chrysler,* 31 U.S.P.Q.2d 1746 (Fed. Cir. 1994).
- 58. ORC* v. Time-Warner, discussed in 26 U.S.P.Q.2d 1718 (D. Del. 1992).
- 59. Scripps v. Baxter,* 729 F. Supp. 1473(D. Del. 1990).
- 60. Exxon v. Lubrizol,* 26 U.S.P.Q.2d 1871 (S.D. Tex. 1993).
- 61. Baxter v. Spectramed,* (C.D. Cal. 1993). (Lyon & Lyon, Los Angeles, California)
- 62. Diasonics* v. Acuson, 1993 U.S. Dist. LEXIS 8871 (N.D. Cal. 1993).
- 63. Concept Design* v. Duplitronics, 1995 U.S. App. LEXIS 848.
- 64. Gentex* v. Donnelly, 27 U.S.P.Q.2d 1714 (W.D. Mich. 1993).
- 65. Sanders* v. Summagraphics, 19 U.S.P.Q.2d 1859 (D. Conn 1991).
- 66. Refac v. Lotus Development,* 1995 U.S. Dist. LEXIS 4678 (S.D.N.Y. 1995).
- 67. Glaxo v. Novopharm,* 29 U.S.P.Q.2d 1126 (E.D. N. C. 1993).
- 68. Transmatic v. Mark IV,* 29 U.S.P.Q.2d 1541 (E.D. Mich. 1993).

- 69. Schneider v. Scimed,* 852 F. Supp. 813 (D. Minn. 1993).
- 70. Teradyne v. Hewlett-Packard,* 1994 U.S. Dist. LEXIS 4806 (N.D. Cal. 1994).
- 71. Motor Wheel* v. Superior (E.D. Mich. 1994). (Jones Day, Cleveland, Ohio)
- 72. InterDigital Technology* v. QUALCOMM, 30 U.S.P.Q.2d 1205 (E.D. Pa. 1994).
- 73. Terumo* v. Cook and Wilson-Cook, (E.D. Va. 1994). (Fish & Richardson, Washington D.C.)
- 74. A & L v. ReSound,* (N.D. Cal. 1995). (Pillsbury Madison, San Francisco, California)
- 75. InterDigital Technology* v. Motorola, (D.Del. 1995). (Dickstein Shapiro, Washington, D.C.)
- 76. Enzo Biochem v. Calgene,* 27 U.S.P.Q.2d 1636 (D. Del 1993).
- 77. Hewlett-Packard* v. GenRad, (D. Mass 1995). (Pennie & Edmonds, New York, N.Y.)
- 78. Johns-Hopkins University v. Cellpro* (jury verdict for Cellpro), (D. Del. 1995). (Lyon & Lyon, Los Angeles, California)
- 79. Varian* v. Lam, (N.D. Cal. 1995). (Fish & Neave, New York, N.Y.)
- 80. Weatherchem Corp. v. J.L. Clark, Inc.,* (U.S.P.Q.2d (N.D. Ohio 1996).
- 81. Odetics v. Storage Technology* (E.D. Va. 1996). (Pennie & Edmonds, Menlo Park, Cal.)
- 82. Emerson v. General Electric,* (E.D. Missouri 1996). (Welsh & Katz, Chicago, Illinois)
- 83. Akro Corp.* v. Ken Luker, (N.D. Ohio 1996). (Bell, Seltzer, Raleigh, North Carolina)
- 84. Bard v. Boston Scientific,* (D. Del. 1997).

(Fish & Richardson, Boston, Mass.)85.

- 86. Labatt v. Molson* (E,D. MI 1997). (Fitzpatrick, Cella, Harper & Scinto, New York, N.Y.)
- 87. R2* v. Ketcho (N.D. Ill. 1997) (Fish & Neave, New York)
- 88. Novo Nordisk* v. Genencor (D. Del. 1998) (Darby & Darby, New York, N.Y.).
- 89. Forest Labs* v. Abbott and Tokyo Tanabe (Fish & Neave, New York, N.Y.)
- 90. In the Matter of Schering-Plough Corp. (FTC Docket No. 9297). (FTC-Washington D.C.)
- 91. Symbol Technologies v. Lemelson (D. Nev. 2003) (Fish & Neave, New York, N.Y.)
- 92. Reiffin v. Microsoft (N.D. Cal. 2003) (Fish & Neave, Palo Alto, California)
- 93. Creo* v. Agfa, (D. Mass. 2003) (Hale & Dorr, New York, N.Y.)
- 94. Zenon Environmental v. United States Filter* (S.D. Cal. 2005) (Wilmer Cutler Pickering Hale & Dorr, Boston Ma.)
- 95. In the Matter of Certain Nor and Nand Flash Memory (ITC 2006) (Wilmer Hale, Washington, DC)

EXHIBIT B

Buchanan Ingersoll & Rooney PC Attorneys & Government Relations Professionals

P.O. Box 1404 Alexandria, VA 22313-1404

Susan M. Dadio 703 838 6531 susan.dadio@bipc.com 1737 King Street, Suite 500 Alexandria, VA 22314-2727 T 703 836 6620 F 703 836 2021 www.buchananingersoll.com

July 2, 2007

VIA ELECTRONIC MAIL

John Josef Molenda, Ph.D. Frommer Lawrence & Haug LLP 745 Fifth Avenue New York, NY 10151

Re: Sepracor Inc. v. Dey, L.P. and Dey, Inc.

Case Nos. 06-113-*** and 06-604-*** (Consolidated)

Dear John:

This is in response to your letter dated June 25, 2007, regarding Dey's identification of Professor Martin Adelman as a potential expert in the above-referenced case.

In accordance with Paragraph 11(a) of the Stipulated Protective Order, Sepracor hereby timely serves the present written objection to the proposed disclosure of any of Sepracor's Confidential Information to Professor Adelman. The United States District Court for the District of Delaware does not permit expert testimony from attorneys regarding patent practice and procedure, nor does it permit expert legal testimony on substantive issues in patent cases. Thus, there is no apparent reason for Dey to disclose Sepracor's Confidential Information to Professor Adelman.

Sincerely,

BUCHANAN INGERSOLL & ROONEY PC

EXHIBIT C

FLH FROMMER LAWRENCE & HAUG LLP

New York

www.fihlaw.com

745 Fifth Avenue

New York, NY 10151 Telephone: (212) 588-0800 Washington, DC Tokyo

Fax: (212) 588-0500

July 5, 2007

John Josef Molenda, Ph.D. JMolenda@flhlaw.com

VIA E-MAIL

Re: Sepracor Inc. v. Dey, L.P., Inc.,

Civil Action Nos. 06-113-*** and 06-604*** (consolidated)

Dear Susan:

This is in response to your letter dated July 2, 2007 concerning Sepracor's objection to disclosure of Sepracor's Confidential Information to Professor Martin Adelman.

We disagree with your assertion that the District of Delaware would preclude Professor Adelman's testimony, and that, as a result, "there is no apparent reason for Dey to disclose Sepracor's Confidential Information to Professor Adelman." Even if the Court were to preclude Professor Adelman from serving as a testifying expert (which we believe it would not), Dey is nonetheless entitled to use Professor Adelman as a consulting expert. Sepracor's objection is therefore without cause.

Please let me know by the close of business tomorrow whether Sepracor objects to the disclosure of Confidential Information to Professor Adelman with cause and the basis for that objection. If we do not hear from you by that time, we will disclose Sepracor Confidential Information to Professor Adelman.

Yours sincerely,

John Josef Molenda

JJM/jjm Attachments

EXHIBIT D

UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

CHAMBERS OF SUE L. ROBINSON CHIEF JUDGE LOCKBOX 31 844 KING STREET U.S.COURTHOUSE WILMINGTON, DELAWARE 19801

Guidelines: Legal Expert Testimony in Patent Cases

In all patent jury trials, the court shows the video "An Introduction to the Patent System" to the jurors in connection with its preliminary jury instructions. The 18 minute video is distributed by the Federal Judicial Center and provides jurors with an overview of patent rights in the United States, patent office procedure and the contents of a patent. Thus, expert testimony from attorneys regarding patent practice and procedure is not required and will not be permitted except in the case of extraordinary circumstances.

"Expert" legal testimony (as opposed to technical testimony) on such substantive issues as invalidity (by anticipation, obviousness, on-sale bar, prior conception, etc.) and claim construction and infringement, generally is not admitted, as descriptions of the law and instructions on the law are matters for the court.

EXHIBIT E

UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

CHAMBERS OF KENT A. JORDAN DISTRICT JUDGE LOCKBOX 10 844 KING STREET U.S. COURTHOUSE WILMINGTON, DELAWARE 19801

Guidelines: Legal Expert Testimony in Patent Cases

In patent jury trials, the court will either provide a brief description of the procedure for obtaining patents or show the video "An Introduction to the Patent System" to the jurors in connection with the preliminary jury instructions. The 18 minute video is distributed by the Federal Judicial Center and provides jurors with an overview of patent rights in the United States, patent office procedure and the contents of a patent. Expert testimony from attorneys regarding patent practice and procedure is not required and will not be permitted, except, perhaps, in the case of truly extraordinary circumstances.

"Expert" legal testimony (as opposed to technical testimony) on such substantive issues as invalidity (by anticipation, obviousness, on-sale bar, prior conception, etc.) and claim construction and infringement will also not be permitted, as descriptions of the law and instructions on the law are matters for the court. This principle also holds for issues tried to the court, such as inequitable conduct.

Not Reported in F.Supp. Not Reported in F.Supp., 1997 WL 158281 (D.Del.) (Cite as: Not Reported in F.Supp.) Page 1

н

Revlon Consumer Products Corp. v. L'Oreal S.A. D.Del.,1997.

Only the Westlaw citation is currently available.
United States District Court,D. Delaware.
REVLON CONSUMER PRODUCTS
CORPORATION, Plaintiff,

v.

L'ORÉAL S.A., Cosmair, Inc., Maybelline, Inc., and Maybelline Sales, Inc., Defendants.

Civil Action No. 96-192 MMS.

March 26, 1997.

Jack Blumenfeld, Jon E. Abramczyk, Morris, Nichols, Arsht & Tunnell, Wilmington, DE, Daniel J. Leffell, Elizabeth J. Holland, Douglas A. Berman, Paul, Weiss, Rifkind, Wharton & Garrison, New York City, John W. Behringer, Fitzpatrick, Cella, Harper & Scinto, of Counsel, for plaintiff.

Rudolph E. Hutz, Stanley C. Macel, III, Connolly, Bove, Lodge & Hutz, Wilmington, DE, Norman H. Stepno, Frederick G. Michaud, Jr., David M. Schlitz, Ronni S. Jillions, Burns, Doane, Swecker & Mathis, L.L.P., Alexandria, VA, Norman F. Oblon, Richard D. Kelly, Jean-Paul Lavalleye, Frank J. West, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., Arlington, VA, of Counsel, for defendants.

MEMORANDUM OPINION
MURRAY M. SCHWARTZ, Senior District Judge.

INTRODUCTION

*1 Revlon Consumer Products Corp. ("Revlon") filed this lawsuit against L'Oréal S.A., Cosmair Inc., Cosmair Canada, Inc., Maybelline, Inc. and Maybelline Sales, Inc. (collectively "defendants") alleging infringement of Revlon's patented composition for transfer resistant lipstick. See Docket Item ("D.I.") 61 (Amended Complaint). Three defendants, Cosmair Inc., Maybelline Inc., and Maybelline Sales Inc., asserted a counterclaim seeking a declaratory judgment that Revlon's patent

is invalid and they have not infringed nor induced infringement.

FN1. Cosmair Canada, Inc. has since been dismissed as a defendant. D.I. 24.

Before the Court is Revlon's motion to preclude the testimony of defendants' patent law expert, John Witherspoon. D.I. 147. According to his report, Mr. Witherspoon proposes to offer opinions on a wide range of issues, including Patent and Trademark Office ("PTO") practice and procedure as well as many substantive areas of patent law. $^{\rm FN2}$ Id., Exh. A at 2. The parties agree Mr. Witherspoon may testify as to PTO practice and procedure. D.I. 154, at 1; D.I. 157 at 2. Revlon asserts, however, the remainder of Mr. Witherspoon's proposed testimony goes to topics inappropriate for expert testimony in a patent case. D.I. 157, at 2. In their answer to Revlon's motion, defendants indicate other than PTO practice and procedure, they wish only to introduce Mr. Witherspoon's testimony on the issue of inequitable conduct. D.I. 154, at 1. Thus, to resolve Revlon's motion, the Court must decide whether to admit testimony by a proffered patent law expert on the topic of inequitable conduct.

> FN2. Specifically, these areas are: "patent infringement, both literal and under the doctrine of equivalents; principles of claim construction and interpretation; prosecution history estoppel; conditions for patentability, including novelty, utility and nonobviousness under 35 U.S.C. §§ 101, 102 and 103; requirements for and purposes of patent specifications and claims under 35 U.S.C. § 112; the prohibition regarding the addition of new matter under 35 U.S.C. § 132; duties and responsibilities of an inventor, his or her attorney or agent, and others substantively preparation involved in the prosecution of a patent application in the PTO; and the prosecution history of the

Not Reported in F.Supp., 1997 WL 158281 (D.Del.)

(Cite as: Not Reported in F.Supp.)

patent in suit." D.I. 147, Exh. A, at 2.

DISCUSSION

I. Inequitable Conduct

Inequitable conduct has been defined by the Federal Circuit Court of Appeals as "an 'affirmative misrepresentation of a material fact, failure to disclose material information, or submission of false material information, coupled with an intent to deceive." *Micro Chemical, Inc. v. Great Plains Chemical Co., Inc.,* 103 F.3d 1538, 1549 (Fed.Cir.1997) (citation omitted); *accord Refac International, Ltd. v. Lotus Development Corp.,* 81 F.3d 1576 (Fed.Cir.1996). "Information is 'material' when there is a substantial likelihood that a reasonable examiner would have considered the information important in deciding whether to allow the application to issue as a patent." *Refac International,* 81 F.3d at 1581.

The proponent of a claim of inequitable conduct must prove "the threshold elements of materiality and intent by clear and convincing evidence." *Micro Chemical, Inc.*, 103 F.3d at 1549. "The district court must then weigh the threshold findings of materiality and intent in light of all the circumstances to determine whether they warrant a conclusion that inequitable conduct occurred." *Id.* "A determination of inequitable conduct is committed to a district court's discretion." *Id.*

II. Expert Testimony

Defendants assert Mr. Witherspoon's testimony as to inequitable conduct may assist the trier of fact and thus is admissible under Federal Rule of Evidence 702. That rule states:

*2 If scientific, technical, or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training, or education, may testify thereto in the form of an opinion or otherwise.

Fed.R.Evid. 702.

Because the admission of expert testimony is a "procedural matter" not unique to patent issues, the law of the Third Circuit Court of Appeals governs this motion, as opposed to the law of the Federal Circuit. *Panduit Corp. v. All States Plastic Manufacturing Co.*, 744 F.2d 1564, 1574-75 (Fed.Cir.1984); *accord National Presto Industries, Inc. v. The West Bend Co.*, 76 F.3d 1185, 1188 n. 2 (Fed.Cir.1996).

The decision whether to admit expert testimony is committed to the discretion of the district court. *United States v. Velasquez*, 64 F.3d 844, 847-48 (3d Cir.1995). As might be gleaned from the rule, several bases exist for excluding expert testimony. They are: "(1) if the testimony will not assist the trier of fact; (2) if scientific [or technical or other specialized] evidence is not sufficiently reliable; and (3) if the particular expert does not have sufficient specialized knowledge to assist the jurors." *Petruzzi's IGA Supermarkets, Inc. v. Darling-Delaware Co.*, 998 F.2d 1224, 1238 (3d Cir.1993); *see also Holbrook v. Lykes Bros. Steamship Co., Inc.*, 80 F.3d 777, 781 (3d Cir.1996).

The Third Circuit Court of Appeals has adopted a broad interpretation of Rule 702; close calls on the admission of expert testimony are to be resolved in favor of admissibility. *Dunn v. Hovic*, 1 F.3d 1362, 1367 (3d Cir.1993). However, "it is not permissible for a witness to testify as to the governing law since it is the district court's duty to explain the law to the jury...." *United States v. Leo*, 941 F.2d 181, 196 (3d Cir.1991). As relevant to Revlon's motion, Mr. Witherspoon's testimony will be inadmissible either if it is not helpful to the trier of fact, or if it constitutes impermissible testimony before the jury as to the governing law.

Defendants have not provided the details of Mr. Witherspoon's proposed testimony on inequitable conduct, beyond the sentence: "Defendants request that Mr. Witherspoon be allowed to testify as to the inequitable conduct issue if the Court determines that Mr. Witherspoon's testimony as a legal expert would assist in its determination." D.I. 154, at 2.

Defendants' answer to Revlon's motion places into issue the currently unsettled question of whether, in this case, the judge or the jury will act as fact-finder on the issue of inequitable conduct.

With respect to that question, the Federal Circuit recently explained:

There are a variety of ways in which the district court may choose to handle the issue of inequitable conduct during a jury trial. Some courts have reserved the entire issue of inequitable conduct unto themselves; some have submitted special interrogatories to the jury on the facts of materiality and intent; and some have instructed the jury to find and weigh the facts of materiality and intent and decide the ultimate question of inequitable conduct.... Absent a clear showing of prejudice, or failure to achieve a fair trial, the district court's choice of procedure will not be disturbed.

*3 Hebert v. Lisle Corp., 99 F.3d 1109, 1114 (Fed.Cir.1996). The court noted in the last instance the parties agreed to submit the entire issue of inequitable conduct to the jury. Id.

Failing to achieve similar agreement of the parties in the present case, the Court will opt to submit to the jury special interrogatories on the facts of materiality and intent. The Court will then weigh the findings on these two elements "in light of all the circumstances," and decide the ultimate question of inequitable conduct. See Micro Chemical, Inc., 103 F.3d at 1549; see also Akzo N.V. v. U.S. International Trade Commission, 808 F.2d 1471, 1481-82 (Fed.Cir.1986) ("Materiality and intent must ... be considered together: the more material the omission or misrepresentation, the less intent that must be shown to reach a conclusion of inequitable conduct.")

As the determination of the Court consists of a 'weighing' of the factual findings on materiality and intent, and then a determination in light of all the circumstances whether inequitable conduct occurred, see Micro Chemical. Inc., 103 F.3d at 1549, it follows that the jury will act as the sole fact-finder on the issue of inequitable conduct. The Court therefore cannot permit Mr. Witherspoon to testify as an expert on inequitable conduct; to do otherwise would usurp the respective functions of the jury and the Court. FN3

> FN3. The Federal Circuit recently noted one of the hazards of permitting expert testimony on patent law:

> We take note of the extent to which ... incorrect law was announced by a patent law expert witness. We encourage exercise of the trial court's gatekeeper authority when parties proffer, through purported experts ... markedly incorrect law.

Hebert, 99 F.3d at 1117.

In accordance with the other cases in this District, Court holds defendants' expert John Witherspoon may testify only as to matters of PTO practice and procedure. See Lucas Aerospace, Ltd. v. Unison Industries, L.P., No. 93-525 (D.Del. March, 9, 1995); General Battery Corp. v. Gould, Inc., 545 F.Supp. 731, 758 n. 30 (D.Del.1982); see also Thorn EMI North America Inc. v. Micron Technology, Inc. No. 92-673 (D.Del. Nov.23, 1993) (McKelvie, J.) (hearing transcript); The Read Corporation v. Portec, Inc., No. 88-29 (D.Del. March 9, 1990) (Roth, J.) (hearing transcript); RCA Corp. v. Data General Corp., No. 84-270 (D.Del. Dec. 17, 1986) (Farnan, J.) (hearing transcript); Guidelines: Legal Expert Testimony in Patent Cases (Robinson, J.). FN4 Mr. Witherspoon may not testify as to substantive issues of patent law, including inequitable conduct. For purposes of clarity, it is noted this holding precludes, among other things, Mr. Witherspoon's proposed testimony regarding the "duties and responsibilities of an inventor, his or her attorney or agent, and others substantively involved in the preparation and prosecution of a patent application in the PTO...." D.I. 147, Exh. A, at 2.

> FN4. While this rule regarding patent experts is followed in this District, it is not uniform throughout the country. Several Federal Circuit cases refer, in passing, to expert testimony that was permitted on the

Not Reported in F.Supp., 1997 WL 158281 (D.Del.)

(Cite as: Not Reported in F.Supp.)

topic of inequitable conduct, see Hebert, 99 F.3d at 1115; Kingsdown Medical Consultants Ltd. v. Hollister, Inc., 863 F.2d 867, 872 (Fed.Cir.1988).

An order will issue consistent with this opinion.

D.Del.,1997.Revlon Consumer Products Corp. v. L'Oreal S.A.Not Reported in F.Supp., 1997 WL 158281

END OF DOCUMENT

(D.Del.)

Not Reported in F.Supp.2d Not Reported in F.Supp.2d, 2004 WL 2106583 (D.Del.)

(Cite as: Not Reported in F.Supp.2d)

н

Syngenta Seeds, Inc. v. Monsanto Co. D.Del.,2004.

Only the Westlaw citation is currently available.
United States District Court,D. Delaware.

SYNGENTA SEEDS, INC., Plaintiff,

v.

MONSANTO CO., Dekalb Genetics Corp., Pioneer Hibred International, Inc., Dow Agrosciences, LLC, and Mycogen Plant Science, Inc. and Agrigenetics, Inc., collectively d.b.a. Mycogen Seeds,

Defendants.

No. Civ.02-1331-SLR.

Sept. 8, 2004.

Paul M. Lukoff, Prickett, Jones & Elliott, Wilmington, DE, for Plaintiff.

Richard L. Horwitz, Potter Anderson & Corroon, LLP, Wilmington, DE, for Defendants.

 $\label{eq:memorandum} \mbox{MEMORANDUM ORDER} \\ \mbox{ROBINSON, J.}$

I. INTRODUCTION

*1 On July 25, 2002, plaintiff Syngenta Seeds, Inc., filed a complaint alleging defendants infringed three of its patents. (D.I.1) Discovery in the action concluded on July 14, 2004, and the case is scheduled for a jury trial commencing on November 29, 2004. (D.I.228) Before me is plaintiff's motion to exclude some of defendants' expert reports. (D.I.220)

II. BACKGROUND

In response to plaintiff's claims, defendants argue, among other things, that plaintiff's patents are invalid due to double patenting, failure to disclose pending applications during interference proceedings and inequitable conduct.

With respect to the motion at issue, plaintiff claims that defendants' experts, John T. Goolkasian, Esq., Martin J. Adelman, Esq., Gerald Bjorge, Esq. and

Dr. Joachim Messing, made conclusions of law and discussed general patent practices and procedures. Defendants assert that in this complicated case the experts are required to understand their defenses. In the alternative, the defendants claim their experts will not testify to all the issues referred to by the expert reports, especially those issues of patent procedure that the court finds would not be helpful to the finder of fact.

Page 1

Mr. Adelman is the expert for Dow AgroSciences, Mycogen Plant Science and Agrigentics. (D.I. 222 at A048) Mr. Borjge issued an expert report for Pioneer Hi-Bred International, Inc. (*Id.* at A011) Mr. Goolkasian is testifying for Monsanto and Dekalb. (*Id.* at A062) All three are lawyers with significant experience in patent law and the United States Patent and Trademark Office ("PTO"). (Id. at A011-A013, A048, A063-A066) All have a technical background as well. (*Id.* at A011, A063)

The reports at issue provide a general overview of patent law and the PTO. Each discusses specific PTO procedures with respect to continuing patent applications, double patenting and interference. (*Id.* at A013-A018, A045, A049-A052, A066-A071, A073-A077, A133-A135) Each expert discusses the prosecution history of the three patents at issue and the role prior history played in the 10 years of prosecution. (*Id.* at A018-A029, A052-A060, A077-A118) In some instances, the experts draw conclusions from the prosecution record, such as, "it appears that both Drs. Koziel and Evola had a duty to tell the patent office about either Dr. Fowler's Patent Applications [sic], and did not comply with that duty." (*Id.* at A118)

Dr. Messing received an M.S. degree in Pharmacy from the Free University of Berlin, and a doctorate degree from the Ludwig Maximilian University of Munich. (*Id.* at A140) He is a member of the Rutgers faculty, and has founded both Rutger's Department of Molecular Biology and Biochemistry, and its Department of Genetics. (Id.) Section VII of Dr. Messing's expert report, entitled

(Cite as: Not Reported in F.Supp.2d)

Not Reported 1:065 Gyr. 20113-JJF

"All of the Patent Claims are Unenforceable Due to the Inequitable Conduct of Syngenta and Its Counsel," discusses the PTO's policy of candor and its application to the plaintiff's duty to disclose certain prior art. (*Id.* at A142) In part A of this section, Dr. Messing concludes that the plaintiff is not entitled to the conception date cited in the three patents. (Id. at A156) In the other parts of Section VII, he concludes that plaintiff did know, or at least should have known, that it was failing to disclose necessary information to the PTO. (Id. at A157-A164)

FN1. Of course, any claims of inequitable conduct will be presented in a bench trial, further obviating the need for legal experts.

III. DISCUSSION

*2 I have issued guidelines for patent litigation that explicitly state, "expert testimony from attorneys regarding patent practice and procedure is not required and will not be permitted except in the case of extraordinary circumstances." (D.I. 222 at A001) In all patent cases tried before me, the jury is shown a Federal Judicial Center video about patent law, PTO policies and procedures. I have determined that this video is a sufficient basis for instructing jurors. I am not convinced that additional information about patent law is required in this case. Therefore, pursuant to this court's guidelines on legal testimony in patent cases, the expert opinions challenged by the plaintiff are excluded.

FN2. These guidelines are also available at http://

www.ded.uscourts.gov/SLRmain.htm.

IV. CONCLUSION

Therefore, at Wilmington this 8th day of September, 2004;

IT IS ORDERED that plaintiff's motion to exclude (D.I.220) is granted.

D.Del.,2004.

Syngenta Seeds, Inc. v. Monsanto Co. Not Reported in F.Supp.2d, 2004 WL 2106583 (D.Del.)

END OF DOCUMENT